This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -11.43% and -0.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Plus (PSTV) Upgraded to Buy: Here's Why
by Zacks Equity Research
Plus (PSTV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Plus (PSTV) delivered earnings and revenue surprises of -229.41% and 42.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Nutriband Inc. (NTRB) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Nutriband (NTRB) delivered earnings and revenue surprises of 7.69% and 6.06%, respectively, for the quarter ended April 2025. Do the numbers hold clues to what lies ahead for the stock?
The Cooper Companies (COO) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
The Cooper Companies (COO) delivered earnings and revenue surprises of 3.23% and 0.67%, respectively, for the quarter ended April 2025. Do the numbers hold clues to what lies ahead for the stock?
Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Alpha Cognition Inc. (ACOG) delivered earnings and revenue surprises of 65.52% and 26.78%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Plus (PSTV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Verve Therapeutics (VERV) delivered earnings and revenue surprises of 50.70% and 362.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -1.92% and 8.71%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of 29.41% and 65.15%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics
by Zacks Equity Research
Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics are part of the Zacks Industry Outlook article.
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
by Kinjel Shah
Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.
Plus (PSTV) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Plus (PSTV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Plus (PSTV) delivered earnings and revenue surprises of -31.37% and 6.49%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug
by Zacks Equity Research
The FDA conditionally accepts Plus Therapeutics' new proprietary name, Reyobiq, for its lead therapeutic candidate. Stock shoots up.
PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy
by Zacks Equity Research
The FDA bestows an Orphan Drug tag to Plus Therapeutics' investigational drug, rhenium (186Re) obisbemeda, for treating leptomeningeal metastases in lung cancer patients.
Theravance Biopharma (TBPH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of 0% and 3.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
ProPhase Labs, Inc. (PRPH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
ProPhase Labs (PRPH) delivered earnings and revenue surprises of -12.90% and 11.56%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Organogenesis (ORGO) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Organogenesis (ORGO) delivered earnings and revenue surprises of 550% and 5.10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 8.22% and 4.44%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
DURECT (DRRX) delivered earnings and revenue surprises of 25% and 1.19%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Plus (PSTV) delivered earnings and revenue surprises of 10.26% and 4.21%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Plus (PSTV) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Plus (PSTV), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Plus (PSTV) delivered earnings and revenue surprises of 0% and 68.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Plus (PSTV) delivered earnings and revenue surprises of -6.67% and 88.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?